|
Match
|
Document |
Document Title |
|
|
7601719 |
Compounds, methods and pharmaceutical compositions for inhibiting PARP
The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat,...
|
|
|
7601718 |
Compositions useful as inhibitors of protein kinases
The present invention provides a compound of formula I:
or a pharmaceutically acceptable salt or mixtures thereof. These compounds are inhibitors of protein kinases, particularly...
|
|
|
7579351 |
Tricyclic amide derivatives
The present invention relates to compounds of formula I
wherein A, G, r and R 1 to R 5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The...
|
|
|
7579348 |
Derivatives of 8-substituted xanthines
The present invention provides compounds and pharmaceutical compositions that are substituted pyridyl-linked-xantbines of formula I
which are selective antagonists of A 2B adenosine receptors...
|
|
|
7579325 |
Drugs containing reduced of vitamin B2
The present invention provides medicines for preventing or treating infectious diseases, sepsis and/or septic shock, which exhibit excellent immunostimulating effects. More specifically, the...
|
|
|
7576073 |
Combined therapy for the treatment of parkinson's disease
The present invention concerns a method and a pharmaceutical composition for treating the symptoms associated to Parkinson's disease. The method and the pharmaceutical composition use a combination...
|
|
|
7569689 |
Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including...
|
|
|
7566714 |
Methods and compositions for the treatment of metabolic disorders
The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and...
|
|
|
7566707 |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula
wherein Y and R 1 to R 4 are defined as in claim 1 , the tautomers, enantiomers,...
|
|
|
7563793 |
Pyrrolo[1,2-a]quinoxalin-5-(4H)-yl)sulfonyls and carbonyls and their use as estrogenic agents
This invention provides estrogen receptor modulators having the structure:
wherein R 1 to R 7 , R 9 , R 10 , X, Y, and Z are as defined in the specification; or a pharmaceutically acceptable...
|
|
|
7563773 |
Anthelmintic oral homogeneous veterinary pastes
This invention provides for, inter alia, oral homogeneous veterinary pastes for the treating, controlling and preventing of endo- and ectoparasite infections in warm-blooded animals or birds, such...
|
|
|
7550465 |
Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds,...
|
|
|
7547699 |
Tetracyclic 6 azapyrazinoindolines as 5HT2C receptor agonists for obesity
The present invention refers to chemical compounds of formula (I)
as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 to R 5 have the significance given in claim 1....
|
|
|
7538112 |
HIV integrase inhibitors
Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R...
|
|
|
7538111 |
Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
The present invention concerns novel benzenesulphonamide compounds, defined by formula I.
Therapeutic compositions comprising the benzenesulphonamide compounds of the invention or salts thereof...
|
|
|
7517883 |
Solubilized topoisomerase poisons
The invention provides compounds of formula I:
wherein
A, B, W, Y, Z, and R 1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention...
|
|
|
7514427 |
1,5,6,-substituted-2-oxo-3-cyano-1,6a-diaza-tetrahydro-fluoranthenes as anti-inflective agents
HIV inhibitory compounds of formula:
salts and stereoisomers thereof, wherein
R 1 and R 2 are hydrogen or optionally substituted C 1-10 alkyl; R 3 is
n is 1, 2 or 3;
...
|
|
|
7511041 |
Fused azole-pyrimidine derivatives
The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the...
|
|
|
7456224 |
Method for treating autism
A method for treating autism comprising the step of administering an effective amount of a medicament characterized as a NMDA-receptor antagonist or a pharmaceutically acceptable salt thereof.
|
|
|
7435735 |
Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors
Hydroxy-substituted pyridopyrrolopyrazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I): (I) wherein...
|
|
|
7432267 |
Fused cyclic modulators of nuclear hormone receptor function
Disclosed are compounds having the formula (I):
including compounds of formulae (Ia) and (Ib):
wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a...
|
|
|
7410969 |
Antitumoral analogs of ET-743
Antitumor compounds have the five membered fused ring ecteinascidin structure of the formula (XIV). The present compounds lack a 1,4-bridging group as found in the ecteinascidins. They have at the...
|
|
|
7396833 |
Indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with...
|
|
|
7381720 |
Substituted quinobenzoxazine analogs
The present invention relates to methods for ameliorating a cell proliferative disorder using quinobenzoxazines analogs having the general formula:
and pharmaceutically acceptable salts,...
|
|
|
7378420 |
Urea derivatives as calcium channel blockers
Derivatives of urea that contain piperazine rings and additional substitution with aromatic groups are effective in ameliorating conditions associated with unwanted calcium ion channel activity.
|
|
|
7371754 |
Tyrosine kinase inhibitors
The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The...
|
|
|
7371753 |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
Disclosed are new dihydropteridinones of general formula (I)
wherein the groups R 1 to R 5 , R a to R c , W, Q 1 and Q 2 have the meanings given in the claims and specification, the isomers...
|
|
|
7348326 |
Heteroaryl fused aminoalkyl imidazole derivatives: selective modulators of GABAa receptors
Disclosed are compounds of the formula:
or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 , are variables defined...
|
|
|
7348027 |
Taste masked veterinary formulation
A method of producing a self-take anthelmintic that includes active components that are undesirable to at least one sense of a target animal. The active ingredients including praziquantel are mixed...
|
|
|
7326709 |
Bicyclic and tricyclic heteroaromatic compounds
Disclosed are compounds of the formula:
and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X 1 , Y and Z are as defined herein. These compounds bind with high selectivity...
|
|
|
7288543 |
Opioid receptor antagonists
A compound of the formula (I) (I) wherein the variables X1 to X6, Ra, Rb, R1 to R7 including R3′, E, p, j, y, z, A, B and C are as described or a pharmaceutically acceptable salt, solvate,...
|
|
|
7268138 |
Compounds, methods and pharmaceutical compositions for inhibiting PARP
The present invention provides compounds which inhibit poly(ADP-ribose) polymerase (“PARP”), compositions containing these compounds and methods for using these PARP inhibitors to treat,...
|
|
|
7265119 |
Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9-pentaene:
and pharmaceutical compositions thereof. The present...
|
|
|
7259167 |
Antimalarial and antiproliferative pharmacophore models, novel tryptanthrin compounds having increased solubility, and methods of making and using thereof
Disclosed herein is a pharmacophore model for antimalarial activity and methods of making and using thereof. The pharmacophore comprises two hydrogen bond acceptor (lipid) functions and two...
|
|
|
7259157 |
N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
Compounds represented by Formula (I):
or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain.
|
|
|
7247630 |
Uses of tricyclic compounds
Novel tricyclic compounds are disclosed having the general structure of Formulas I or II:
were R1, R2 and R3 are defined in the written description of the invention. The compounds are useful...
|
|
|
7238702 |
Dihydroquinazolinones as 5HT modulators
The present invention relates to modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating obesity using such compounds and compositions.
|
|
|
RE39680 |
Substituted heterocycle fused gamma-carbolines
The present invention is directed to certain novel compounds represented by structural Formula (I)
or pharmaceutically acceptable salt forms thereof, wherein R 1 , R 5 , R 6a , R 6b , R 7 , R...
|
|
|
7208494 |
5HT2c receptor agonists
The present invention provides piperazine derivatives of formula (I)
as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 to R 5 have the significance given in the...
|
|
|
7208490 |
Tricyclic tetrahydroquinoline antibacterial agents
The invention includes tetrahydroquinoline and related compounds of formula I, and pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and...
|
|
|
7205300 |
Aryl fused azapolycyclic compounds
This invention is directed to compounds of the formula (I):
and their pharmaceutically acceptable salts, wherein R 1 , R 2 , and R 3 are as defined herein; intermediates for the synthesis of...
|
|
|
7202246 |
Spiro-rifamycin derivatives targeting RNA polymerase
Compounds of the current invention relate to rifamycin derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. More specifically, compounds of the...
|
|
|
7202245 |
Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines
The present invention provides compounds of formula (I)
the prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein R a , R b , R 1 , and R 2 are as...
|
|
|
7192931 |
Treatment of demyelinating diseases
This invention relates to methods for the treatment or prevention of central nervous system (CNS) cell damage and functional damage in mammals due to demyelinating disease including multiple...
|
|
|
7189724 |
Quinoxaline derivatives having antiviral activity
The invention provides substituted quinoxalines having the general formulas
where R 1 , R 2 , R 3 , and R 4 are, inter alia, alkyl, aryl, or heteroaryl groups; Z is NH or O; and X is, inter...
|
|
|
7183282 |
Substituted heterocycle fused γ-carbolines
The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I)
or pharmaceutically acceptable salt forms...
|
|
|
7182958 |
β-carboline pharmaceutical compositions
Formulations containing a PDE5 inhibitor, a water-soluble diluent, a lubricant, a hydrophilic binder, a disintegrant, and optional microcrystalline cellulose and/or a wetting agent, and their use...
|
|
|
7163939 |
Macrocyclic kinase inhibitors
Compounds having the formula
are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using...
|
|
|
7160888 |
[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
This invention relates to compounds of the formula 1
wherein G, D, A, Z, Q, X, Y, R 1 , and R 4 through R 7 are defined as in the specification, processes for preparing the same and...
|
|
|
7144882 |
Aryl fused azapolycyclic compounds
This invention is directed to compounds of the formula (I):
and their pharmaceutically acceptable salts, wherein R 1 , R 2 , and R 3 are as defined herein; intermediates for the synthesis of...
|